The present results argue that several tyrosine kinase inhibitors (TKIs) with known Src inhibitory activities e.g., bosutinib, dasatinib, effectively block MCL-1 antagonist-mediated MCL-1 up-regulation, and in so doing, synergistically potentiate the activity of these agents against AML cells. Here, SRC is linked to acute myeloid leukemia.